RCS_SPI-POZ 201

A Phase 2 Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC

The purpose of this study is to evaluate the efficacy and tolerability of poziotinib in patients with HER2-positive metastatic breast cancer who have received at least 2 prior HER2-directed treatment regimens.
Phase II
NCT02659514
Cancer
Breast
James Lechner, M.D.
Spectrum Pharmaceuticals, Inc
Meley Pine
  • Providence Regional Cancer System - Lacey